Abstrakt

Przypisy

• 1. Bridges C.B., Katz J.M., Seto W.H., Chan P.K., Tsang D., Ho W., MakK.H., Lim W., Tam J.S., Clarke M., Williams S.G., Mounts A.W., BreseeJ.S., Conn L.A., Rowe T. et al.: Risk of influenza A (H5N1) infectionamong health care workers exposed to patients with influenza A(H5N1), Hong Kong. J. Infect. Dis., 2000; 181: 344-348
  Google Scholar
• 2. Brydak L.: Influenza. Myth or a real threat? Termedia Ed., Warsaw2008: 23-87
  Google Scholar
• 3. Center for Disease Prevention and Control (CDC). Influenza antiviralmedications: summary for clinicians. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (21 April 2015)
  Google Scholar
• 4. Center for Disease Prevention and Control (CDC). Prevention andcontrol of seasonal influenza with vaccines: recommendations ofthe Advisory Committee on Immunization Practices-United States,2013-14. http://www.cdc.gov/flu/professionals/acip/index.htm.(24 April 2015)
  Google Scholar
• 5. Center for Disease Prevention and Control (CDC). Recommendeddosage and duration of influenza antiviral medications for treatmentor chemoprophylaxis. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#dosage(25 April 2015)
  Google Scholar
• 6. European Medicines Agency (EMA). Updated review of influenzaantiviral medicinal products for potential use during pandemic bythe Committee for Medical Products for Human Use (CHMP) of theEuropean Medicine Agency. ww.ema.europa.eu/ema/index.jsp (12April 2014)
  Google Scholar
• 7. Farrukee R., Leang S.K., Butler J., Lee R.T., Maurer-Stroh S., TilmanisD., Sullivan S., Mosse J., Barr I.G., Hurt A.C.: Influenza viruseswith B/Yamagata- and B/Victoria-like neuraminidases are differentiallyaffected by mutations that alter antiviral susceptibility. J.Antimicrob. Chemother., 2015; 70: 2004-2012
  Google Scholar
• 8. Gubareva L.V.: Molecular mechanisms of influenza viruses resistanceto neuraminidase inhibitors. Virus Res., 2004; 103: 199-203
  Google Scholar
• 9. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., WebsterR.G.: Evidence for zanamivir resistance in an immunocompromisedchild infected with influenza B virus. J. Infect. Dis., 1998; 178:1257-1262
  Google Scholar
• 10. Hayden F.G., Gubereva L.V., Monto A.S., Klein T.C., Elliot M.J.,Hammond J.M., Sharp S.J., Ossi M.J.; Zanamivir Family Study Group:Inhaled zanamivir for the prevention of influenza in families. N.Engl. J. Med., 2000; 343: 1282-1289
  Google Scholar
• 11. Hayden F.G., Belshe R., Villanueva C., Lanno R., Hughes C., SmallI., Dutkowski R., Ward P., Carr J.: Management of influenza in households:a prospective, randomized comparison of oseltamivir treatmentwith or without postexposure prophylaxis. J. Infect. Dis., 2004;189: 440-449
  Google Scholar
• 12. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., HayA.J., Zambon M.C.: Emergence of resistance to oseltamivir amonginfluenza A(H1N1) viruses in Europe. Euro. Surveill., 2008; 13: 1-2
  Google Scholar
• 13. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., NguyenK.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T.,Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y.: Avian flu: isolationof drug resistant H5N1 virus. Nature, 2005; 437: 1108
  Google Scholar
• 14. Louie J.K., Yang S., Acosta M., Yen C., Samuel M.C., SchechterR., Guevara H., Uyeki T.M. Treatment with neuraminidase inhibitorsfor critically ill patients with influenza A (H1N1)pdm09. Clin. Infect.Dis., 2012; 55: 1198-1204
  Google Scholar
• 15. McKimm-Breschkin J.L.: Resistance of influenza viruses to neuraminidaseinhibitors. Antiviral Res., 2000; 47: 1-17
  Google Scholar
• 16. McKimm-Breschkin J.L., Williams J., Barrett S., Jachno K., McDonaldM., Mohr P.G., Saito T., Tashiro M.: Reduced susceptibility to allneuraminidase inhibitors of influenza H1N1 viruses with haemagglutininmutations and mutations in non-conserved residues ofthe neuraminidase. J. Antimicrob. Chemother., 2013; 68: 2210-2221
  Google Scholar
• 17. Monto A.S., Fleming D.M., Henry D., de Groot R., Makela M.,Klein T., Elliott M., Keene O.N., Man C.Y.: Efficacy and safety of theneuraminidase inhibitor zanamivir in the treatment of influenza Aand B virus infection. J. Infect. Dis., 1999; 180: 254-261
  Google Scholar
• 18. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W.,Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G.,Zambon M.: Detection of influenza viruses resistant to neuraminidaseinhibitors in global surveillance during the first 3 years of theiruse. Antimicrob. Agents Chemother., 2006; 50: 2395-2402
  Google Scholar
• 19. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., CarewiczO., Mercier C.H., Rode A., Kinnersley N., Ward P.: Efficacy and safetyof oseltamivir in treatment of acute influenza: a randomized controlledtrial. Lancet, 2000; 355: 1845-1850
  Google Scholar
• 20. Nicoll A., Ciancio B., Kramarz P., Influenza Project Team: Observedoseltamivir resistance in seasonal influenza viruses in Europeinterpretation and potential implications. Euro. Surveill., 2008;13: 1-2
  Google Scholar
• 21. Nitsch-Osuch A., Brydak L.B., Wardyn A.K.: Neuraminidase inhibitorsin prophylaxis and treatment of influenza. Pol. Merkur.Lekarski, 2008; 25: 67-73
  Google Scholar
• 22. Norberg P., Lindh M., Olofsson S.: Published sequences do notsupport transfer of oseltamivir resistance mutations from avianto human influenza A virus strains. BMC Infect. Dis., 2015; 15: 162
  Google Scholar
• 23. Okomo-Adhiambo M., Sleeman K., Lysen C., Nguyen X.T., XuX., Li Y., Klimov A.I., Gubareva L.V.: Neuraminidase inhibitor susceptibilitysurveillance of influenza viruses circulating worldwideduring 2011 Southern Hemisphere season. Influenza Other Respir.Viruses, 2013; 7: 645-658
  Google Scholar
• 24. Rasmussen S.A,. Kissin D.M., Yeung L.F., MacFarlane K., Chu S.Y.,Turcios-Ruiz R.M., Mitchell E.W., Williams J., Fry A.M., Hageman J.,Uyeki T.M., Jamieson D.J., Pandemic Influenza and Pregnancy WorkingGroup: Preparing for influenza after 2009 H1N1: special considerationsfor pregnant women and newborns. Am. J. Obstet. Gynecol.,2011; 204 (Suppl.1): S13-S20
  Google Scholar
• 25. Reece P.A.: Neuraminidase inhibitor resistance in influenza viruses.J. Med. Virol., 2007; 79: 1577-1586
  Google Scholar
• 26. Schultsz C., Dong V.C., Chau N.V., Le N.T., Lim W., Thanh T.T.,Dolecek C., de Jong M.D., Hien T.T., Farrar J.: Avian influenza H5N1and healthcare workers. Emerg. Infect. Dis., 2005; 11: 1158-1159
  Google Scholar
• 27. Siston A.M., Rasmussen S.A., Honein M.A., Fry A.M., Seib K.,Callaghan W.M., Louie J., Doyle T.J., Crockett M., Lynfield R., MooreZ., Wiedeman C., Anand M., Tabony L., Nielsen C.F. et al.: Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in theUnited States. JAMA, 2010; 303: 1517-1525
  Google Scholar
• 28. Takashita E., Meijer A., Lackenby A., Gubareva L., Rebelo-deAndradeH., Besselaar T., Fry A., Gregory V., Leang S.K., Huang W.,Lo J., Pereyaslov D., Siqueira M.M., Wang D., Mak G.C.: Global updateon the susceptibility of human influenza viruses to neuraminidaseinhibitors, 2013-2014. Antiviral Res., 2015; 117: 27-38
  Google Scholar
• 29. Thorlund K., Award T., Boivin G., Thabane L.: Systematic reviewof influenza resistance to the neuraminidase inhibitors. BMC Infect.Dis., 2011; 11: 134
  Google Scholar
• 30. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., BettisR., Riff D., Singh S., Kinnersley N., Ward P., Mills R.G.: Efficacy andsafety of the oral neuraminidase inhibitor oseltamivir in treatingacute influenza: a randomized controlled trial. JAMA, 2000;283: 1016-1024
  Google Scholar
• 31. Varghese J.N., Smith P.W., Sollis S.L., Blick T.J., Sahasrabudhe A.,McKimm-Breschkin J.L., Colman P.M.: Drug design against a shiftingtarget: a structural basis for resistance to inhibitors in a variant ofinfluenza virus neuraminidase. Structure, 1998; 6: 735-746
  Google Scholar
• 32. Ward P., Small I., Smith J., Suter P., Dutkowski R.: Oseltamivir(Tamiflu) and its potential for use in the event of an influenza pandemic.J. Antimicrob. Chemother., 2005; 55 (Suppl.1): i5-i25
  Google Scholar
• 33. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., DutkowskiR., Ipe D., Mills R.G., Ward P.: Oral oseltamivir treatment of influenzain children. Pediatr. Infect. Dis. J., 2001; 30: 127-133
  Google Scholar
• 34. World Health Organization (WHO). Human infection with avianinfluenza A(H7N9) virus – China. http://www.who.int/csr/don/14-April-2015-avian-influenza-china/en/ (24 April 2015)
  Google Scholar
• 35. World Health Organization (WHO). Avian influenza situationin Egypt – update, 18 January 2007. www.who.int/csr/don/2007(24 April 2014)
  Google Scholar
• 36. World Health Organization (WHO). Background and summaryof human infection with influenza A(H7N9) virus. http://www.who.int/influenza/human_animal_interface/latest_update_h7n9/en/ (24 April 2014)
  Google Scholar
• 37. World Health Organization (WHO). Issues new guidelines forthe avian flu virus. www.who.int (24 April 2013)
  Google Scholar
• 38. Yen H.L., Hoffmann E., Taylor G., Scholtissek C., Monto A.S.,Webster R.G., Govorkova E.A.: Importance of neuraminidase activesiteresidues to the neuraminidase inhibitor resistance of influenzaviruses. J. Virol., 2006; 80: 8787-8795
  Google Scholar
• 39. Yu H., Feng Z., Uyeki T.M., Liao Q., Zhou L., Feng L., Ye M., XiangN., Huai Y., Yuan Y., Jiang H., Zheng Y., Gargiullo P., Peng Z., Feng Y.et al.: Risk factors for severe illness with 2009 pandemic influenzaA (H1N1) virus infection in China. Clin. Infect. Dis., 2011; 52: 457-465
  Google Scholar
• 40. Yuen K.Y., Wong S.S.: Human infection by avian influenza AH5N1. Hong Kong Med. J., 2005; 11: 189-199
  Google Scholar

Pełna treść artykułu